Los Angeles Capital Management & Equity Research Inc. purchased a new position in shares of Aratana Therapeutics, Inc. (NASDAQ:PETX) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 19,605 shares of the biopharmaceutical company’s stock, valued at approximately $184,000. Los Angeles Capital Management & Equity Research Inc. owned approximately 0.06% of Aratana Therapeutics as of its most recent filing with the SEC.
Several other large investors have also recently added to or reduced their stakes in the stock. Deere & Co. purchased a new stake in Aratana Therapeutics during the second quarter worth about $404,000. American International Group Inc. increased its position in shares of Aratana Therapeutics by 10.6% in the second quarter. American International Group Inc. now owns 19,201 shares of the biopharmaceutical company’s stock worth $121,000 after buying an additional 1,841 shares during the period. Alliancebernstein L.P. increased its position in shares of Aratana Therapeutics by 38.1% in the second quarter. Alliancebernstein L.P. now owns 39,150 shares of the biopharmaceutical company’s stock worth $247,000 after buying an additional 10,800 shares during the period. Trexquant Investment LP bought a new position in shares of Aratana Therapeutics during the second quarter worth about $188,000. Finally, BlackRock Institutional Trust Company N.A. increased its position in shares of Aratana Therapeutics by 14.4% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 869,516 shares of the biopharmaceutical company’s stock worth $5,495,000 after buying an additional 109,243 shares during the period. Institutional investors and hedge funds own 77.35% of the company’s stock.
Aratana Therapeutics, Inc. (NASDAQ:PETX) traded down 1.41% on Friday, reaching $7.71. The company had a trading volume of 148,829 shares. The stock’s market capitalization is $285.61 million. The stock’s 50 day moving average is $7.70 and its 200-day moving average is $8.21. Aratana Therapeutics, Inc. has a 1-year low of $2.56 and a 1-year high of $10.73.
Aratana Therapeutics (NASDAQ:PETX) last released its quarterly earnings results on Thursday, November 3rd. The biopharmaceutical company reported ($0.38) EPS for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.10. Aratana Therapeutics had a negative return on equity of 19.87% and a negative net margin of 60.32%. During the same period in the previous year, the firm earned ($1.58) earnings per share. On average, equities analysts predict that Aratana Therapeutics, Inc. will post ($0.72) EPS for the current fiscal year.
A number of research analysts recently issued reports on PETX shares. Zacks Investment Research downgraded Aratana Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, October 13th. Jefferies Group LLC reiterated a “buy” rating and set a $11.00 price objective (down from $13.00) on shares of Aratana Therapeutics in a research note on Friday, November 18th. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $10.64.
In other Aratana Therapeutics news, insider Peter Steven St sold 50,000 shares of the stock in a transaction dated Thursday, December 15th. The stock was sold at an average price of $7.63, for a total value of $381,500.00. Following the completion of the sale, the insider now directly owns 592,793 shares in the company, valued at $4,523,010.59. The transaction was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 6.70% of the company’s stock.
Aratana Therapeutics Company Profile
Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.
Want to see what other hedge funds are holding PETX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aratana Therapeutics, Inc. (NASDAQ:PETX).